Get the Stockscreener App
1.36
6.21%
-0.09
Calidi Biotherapeutics Inc stock is traded at $1.36, with a volume of 1.41M.
It is down -6.21% in the last 24 hours and down -40.61% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$1.45
Open:
$1.35
24h Volume:
1.41M
Relative Volume:
0.96
Market Cap:
$25.63M
Revenue:
-
Net Income/Loss:
$-23.36M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-26.49%
1M Performance:
-40.61%
6M Performance:
-30.26%
1Y Performance:
-92.44%
1-Day Range:
$1.27
$1.49
1-Week Range:
$1.27
$1.858
52-Week Range:
$0.73
$18.50
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
1.36 | 25.63M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Biotherapeutics CEO Allan Camaisa sells $16,200 in stock - Investing.com
Calidi Biotherapeutics prices $7.5M secondary offering - MSN
Calidi Biotherapeutics Inc (CLDI-A) QuotePress Release - The Globe and Mail
Calidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care - Barchart
UMACUnusual Machines, Inc. Latest Stock News & Market Updates - StockTitan
Calidi Biotherapeutics (NYSE American: CLDI) Shares Data Supporting Proprietary Systemic Antitumor Platform - Barchart
Calidi Biotherapeutics announces pricing of $7.5M public offering of common stock - MSN
Calidi Biotherapeutics (NYSE American: CLDI) Raises $7.5 Million Through Public Stock Offering - Barchart
If You Don’t Buy Calidi Biotherapeutics Inc (AMEX: CLDI) Now, You’ll Kick Yourself Later - Stocks Register
Calidi Biotherapeutics Reveals Promising Virotherapy Data - TipRanks
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer - EIN News
Calidi presents data on RTNova systemic technology in metastatic lung cancer - TipRanks
Calidi Bio's RTNova Shows Promise in Metastatic Lung Cancer Treatment Breakthrough | CLDI Stock News - StockTitan
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock - The Manila Times
Calidi Biotherapeutics Raises $7.5M Through Public Offering of 4.4M Shares | CLDI Stock News - StockTitan
Pre-market Movers: GANX, TFFP, AKYA, CLDI... - RTTNews
SEC Form 424B5 filed by Calidi Biotherapeutics Inc. - Quantisnow
Calidi prices 4.4M shares at $1.69 in public offering - TipRanks
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock - The Manila Times
Calidi Biotherapeutics Raises $7.5M in Public Offering for Clinical Trials | CLDI Stock News - StockTitan
Calidi announces common stock offering, no amount given - TipRanks
Calidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer News - MarketWatch
Calidi Biotherapeutics plans stock offering - Investing.com India
Calidi Biotherapeutics plans stock offering By Investing.com - Investing.com Canada
Calidi Biotherapeutics Announces Proposed Public Offering - The Manila Times
Calidi Biotherapeutics Launches Public Stock Offering to Fund Corporate Growth | CLDI Stock News - StockTitan
Calidi Biotherapeutics Advances with FDA Clearance and Funding - TipRanks
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results - The Manila Times
Calidi Biotherapeutics’ $2.1 Million Shares Offering - Global Legal Chronicle
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Calidi Biotherapeutics (NYSE:CLDI) - Defense World
CLDICalidi Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Calidi Biotherapeutics’ (NYSE American: CLDI) Groundbreaking Cancer Treatment on RedChip’s Bloomberg TV Program - Barchart
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Calidi to present data supporting RTNova at upcoming conferences - TipRanks
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences - The Manila Times
Calidi to sell 2.05M shares at $1.00 in registered direct offering - Yahoo Finance
Calidi Biotherapeutics stock tumbles on $2M securities offering - MSN
CLDI stock touches 52-week low at $0.95 amid sharp annual decline By Investing.com - Investing.com South Africa
CLDI stock touches 52-week low at $0.95 amid sharp annual decline - Investing.com
Why Calidi Biotherapeutics (CLDI) Stock Is Down 13% - Benzinga
Calidi Biotherapeutics secures $2 million in equity financing - Investing.com
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement - The Manila Times
Calidi Biotherapeutics Faces Warrant Delisting by NYSE - Yahoo Finance
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) - ForexTV.com
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Cap:
|
Volume (24h):